136 related articles for article (PubMed ID: 18567977)
1. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder.
Hoge EA; Worthington JJ; Kaufman RE; Delong HR; Pollack MH; Simon NM
CNS Spectr; 2008 Jun; 13(6):522-7. PubMed ID: 18567977
[TBL] [Abstract][Full Text] [Related]
2. An open-label trial of risperidone augmentation for refractory anxiety disorders.
Simon NM; Hoge EA; Fischmann D; Worthington JJ; Christian KM; Kinrys G; Pollack MH
J Clin Psychiatry; 2006 Mar; 67(3):381-5. PubMed ID: 16649823
[TBL] [Abstract][Full Text] [Related]
3. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings.
Simon NM; Connor KM; LeBeau RT; Hoge EA; Worthington JJ; Zhang W; Davidson JR; Pollack MH
Psychopharmacology (Berl); 2008 May; 197(4):675-81. PubMed ID: 18246327
[TBL] [Abstract][Full Text] [Related]
4. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.
Simon JS; Nemeroff CB
J Clin Psychiatry; 2005 Oct; 66(10):1216-20. PubMed ID: 16259533
[TBL] [Abstract][Full Text] [Related]
5. The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression.
Dording C; Cassiello C; King F; Pencina M; Fava M; Mischoulon D
Int Clin Psychopharmacol; 2013 Sep; 28(5):238-44. PubMed ID: 23764521
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients.
Worthington JJ; Kinrys G; Wygant LE; Pollack MH
Int Clin Psychopharmacol; 2005 Jan; 20(1):9-11. PubMed ID: 15602109
[TBL] [Abstract][Full Text] [Related]
7. Fluvoxamine pharmacotherapy of anxiety disorders in later life: preliminary open-trial data.
Wylie ME; Miller MD; Shear MK; Little JT; Mulsant BH; Pollock BG; Reynolds CF
J Geriatr Psychiatry Neurol; 2000; 13(1):43-8. PubMed ID: 10753007
[TBL] [Abstract][Full Text] [Related]
8. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study.
Schüle C; Baghai TC; Eser D; Hecht S; Hermisson I; Born C; Häfner S; Nothdurfter C; Rupprecht R
World J Biol Psychiatry; 2007; 8(2):112-22. PubMed ID: 17455104
[TBL] [Abstract][Full Text] [Related]
9. Ziprasidone as an augmenting agent in the treatment of anxiety-spectrum disorders.
Crane DL
CNS Spectr; 2005 Mar; 10(3):176-9. PubMed ID: 15744218
[TBL] [Abstract][Full Text] [Related]
10. An open-label study of tiagabine as augmentation therapy for anxiety.
Schwartz TL; Azhar N; Husain J; Nihalani N; Simionescu M; Coovert D; Jindal S; Tirmazi S
Ann Clin Psychiatry; 2005; 17(3):167-72. PubMed ID: 16433059
[TBL] [Abstract][Full Text] [Related]
11. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive aripiprazole in treatment-resistant bipolar depression.
Ketter TA; Wang PW; Chandler RA; Culver JL; Alarcon AM
Ann Clin Psychiatry; 2006; 18(3):169-72. PubMed ID: 16923655
[TBL] [Abstract][Full Text] [Related]
13. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder.
Marcus RN; Owen R; Kamen L; Manos G; McQuade RD; Carson WH; Aman MG
J Am Acad Child Adolesc Psychiatry; 2009 Nov; 48(11):1110-1119. PubMed ID: 19797985
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness.
Katzman MA
J Affect Disord; 2011 Jan; 128 Suppl 1():S11-20. PubMed ID: 21220076
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder.
Suppes T; McElroy SL; Sheehan DV; Hidalgo RB; Cosgrove VE; Gwizdowski IS; Feldman NS
J Clin Psychiatry; 2014 Jan; 75(1):77-84. PubMed ID: 24345758
[TBL] [Abstract][Full Text] [Related]
16. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
Lin CH; Lin SH; Jang FL
J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
[TBL] [Abstract][Full Text] [Related]
17. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
[TBL] [Abstract][Full Text] [Related]
18. Aripiprazole augmentation for treatment of patients with inadequate antidepressants response.
Pae CU; Patkar AA; Jun TY; Lee C; Masand PS; Paik IH
Depress Anxiety; 2007; 24(7):522-6. PubMed ID: 17111388
[TBL] [Abstract][Full Text] [Related]
19. Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting.
Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS
Int Clin Psychopharmacol; 2014 Mar; 29(2):116-9. PubMed ID: 24108149
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study.
Jon DI; Kim DH; Seo HJ; Kwon YJ; Kim MD; Yang JC; Suh HS; Min KJ; Pae CU; Bahk WM
Clin Neuropharmacol; 2013; 36(5):157-61. PubMed ID: 24045606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
